SCHEMBL17027372

SCHEMBL17027372

O=C1CCOc2ccc(B(O)O)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 10/20 0.50
MAOA P21397 1/20 0.50
GRM5 P41594 6/20 0.40
HTR1A P08908 1/20 0.38
CYP2D6 P10635 1/20 0.38
SLC6A4 P31645 1/20 0.38
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ABL1 P00519 1/20 0.35
MET P08581 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
FABP6 P51161 1/20 0.33
ERN1 O75460 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2981516 0.77 MAOB (0.74) MAOBMAOAGRM5NPC1ALDH1A1
SCHEMBL17049537 0.77 MAOB (0.50) MAOBMAOAGRM5HTR1ACYP2D6
SCHEMBL8895 0.75 PRKCI (0.51) NPC1RAB9ASMN1; SMN2ERN1
SCHEMBL6293635 0.75 ALDH1A1 (0.51) MAOBMAOAGRM5NPC1ALDH1A1
SCHEMBL1346998 0.74 HTR1A (0.49) MAOBMAOAGRM5HTR1ACYP2D6
SCHEMBL67612 0.74 MAOB (0.50) MAOBMAOAGRM5HTR1ACYP2D6
SCHEMBL16789730 0.74 MAOB (0.50) MAOBMAOAGRM5HTR1ACYP2D6
SCHEMBL4476431 0.74 MAOB (0.50) MAOBMAOAGRM5NPC1ALDH1A1
SCHEMBL69670 0.74 MAOB (0.50) MAOBMAOAGRM5NPSR1
SCHEMBL30451384 0.74 MAOB (0.50) MAOBMAOAGRM5NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834566-B2 Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2017-12-05 US disclosed
EP-3152215-A1 PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION ViiV Healthcare UK (No.5) Limited (GB) 2017-04-12 EP disclosed
US-20170057977-A1 PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2017-03-02 US disclosed
WO-2015126743-A1 PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170057977-A1 PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION TYMP, TK1, TYMS MAOB 2223/4885MAOA 2744/4885GRM5 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.